EL7.AI
StocksMedium•18 November 2026•
4 min read

Prenetics Revenue Reaches $64.1 Million in Third Quarter, Up 228% Year Over Year

Key Facts

1Prenetics' third-quarter revenue was $64.1 million, up approximately 228% year over year.
2IM8 recorded third-quarter revenue of $62.9 million, up approximately 266% year over year, and posted its seventh consecutive record quarter.
3The loss for the period was $25.4 million, while adjusted EBITDA loss reached $12.7 million, or 20% of revenue.
4Adjusted free cash flow was positive at $4.1 million, against net cash used in operating activities of $27.5 million.
5The company maintained its total 2026 revenue forecast at $220–230 million and is targeting IM8 revenue of $400 million or more in 2027.

Prenetics announced on November 18 that total revenue reached $64.1 million in the third quarter of 2026, an increase of approximately 228% year over year, exceeding the high end of the guidance range it announced in August. The company said the results came as its health and wellness unit, IM8, continued to expand, and quarterly revenue exceeded its previous estimates. Prenetics had forecast total quarterly revenue of between $63 and $64 million, putting the result slightly above the top of that range. The performance puts annual revenue targets at the forefront of investor attention as the company continues to fund growth in its core unit. The company left its 2026 revenue outlook unchanged.

IM8 contributed most of the quarter's revenue, recording $62.9 million, up approximately 266% year over year and above its prior guidance range of $61.5 to $62.5 million. Prenetics said this marked the unit's seventh consecutive record quarter. The company's second-quarter revenue was $46.5 million, including $45 million from IM8, which then posted quarter-over-quarter growth of 33.2%. The comparison shows the unit's revenue continued to rise from the second to the third quarter, while it remained the main driver of reported revenue. In August, the company had forecast total third-quarter revenue of between $63 and $64 million.

Prenetics said September was IM8's strongest month on record at that point, with revenue of $23.7 million. The company estimated the annualized revenue run rate based on the month's performance at approximately $284 million. That annualized rate reflects the pace of one month projected over a year; it does not represent revenue earned over a full year. In August, the company had raised its total 2026 revenue forecast to a range of $220–230 million, with IM8 revenue expected to be between $215 and $222 million. Third-quarter performance and the quarter's final month provide context for those forecasts, which the company said remain in place.

On profitability, Prenetics reported a loss for the period of $25.4 million, including a non-cash loss of $7.2 million from the fair value of warrant liabilities. Adjusted EBITDA loss was $12.7 million, equivalent to 20% of revenue, compared with 39% in the second quarter. The company said adjusted free cash flow was positive at $4.1 million, while it also recorded net cash used in operating activities of $27.5 million. It explained that the adjusted cash flow calculation includes net proceeds of $31.6 million from the General Catalyst facility. The adjusted figure therefore reflects funding available under the facility and does not represent cash generated by operations alone.

Chief Executive Danny Yeung said a group of 27,000 customers acquired in the company's first full quarter had generated cumulative gross profit equivalent to approximately 4.1 times their acquisition cost in less than two years. Yeung linked this result to the company's decision to increase investment in customer acquisition. This is consistent with raising the estimate for adjusted EBITDA loss in the second half of 2026 to $30–35 million, compared with the August forecast of $8–12 million. The company attributed the increase to additional investment in customer acquisition. The second-half guidance therefore combines higher spending on expansion with an improvement in adjusted EBITDA loss as a share of revenue in the third quarter.

Prenetics is targeting total revenue of between $220 and $230 million in fiscal 2026, and an IM8 year-end annualized revenue run rate of $300 million or more. For fiscal 2027, the company said it expects IM8 revenue of at least $400 million. It set the launch of IM8 Hydration for the first quarter of 2027 and the launch of Care Bears by IM8 for the first half of the same year. It is also targeting entry into retail and the Chinese market by the end of 2027, and said these initiatives are not included in its IM8 revenue forecast for 2027. The company had scheduled a live webcast to discuss its third-quarter results on November 18 at 8:30 a.m. Eastern Time.